Venture Everywhere Podcast: Niamh O'Hara with Cristian Ponce
Niamh O'Hara, co-founder and CEO of Biotia, chats with Cristian Ponce, co-founder and CEO of Tetsuwan Scientific on episode 94: Biotia Fighting Infectious Diseases.
In episode 94 of Venture Everywhere the host is Cristian Ponce the CEO of Tetsuwan Scientific, an early-stage company developing software to help scientists operate laboratory automation systems. He talks with Dr. Niamh O’Hara, co-founder and CEO of Biotia, a healthtech company using genomics and AI to fight infectious diseases. She shares how a vision to modernize diagnostics and close the gap in infectious disease detection inspired her to spin Biotia out of Cornell Tech and bring precision metagenomics to market. She opens up about how Biotia bridges the worlds of science and entrepreneurship to accelerate the future of infectious disease diagnostics.
In this episode, you will hear:
Advancing infectious disease testing with genomics and AI
Turning academic research into scalable healthtech innovation
Building faster, more precise pathogen detection tools
Combating antimicrobial resistance through smarter diagnostics
Expanding into women’s health and clinical partnerships
If you liked this episode, please give us a rating wherever you found us. To learn more about our work, visit Everywhere.vc and subscribe to our Founders Everywhere Substack. You can also follow us on YouTube, LinkedIn and Twitter for regular updates and news.
TRANSCRIPT
00:00:04 VO: Everywhere Podcast Network.
00:00:14 Jenny Fielding: Hi, and welcome to the Everywhere Podcast. We’re a global community of founders and operators who’ve come together to support the next generation of builders. So the premise of the podcast is just that, founders interviewing other founders about the trials and tribulations of building a company. I hope you enjoy the episode.
00:00:33 Cristian: Welcome to the Venture Everywhere podcast. I’m Cristian. I’m the CEO of Tetsuwan Scientific, an early stage company that develops software to help scientists operate laboratory automation systems. Our goal is to enable scientists to remotely interface with these systems so they conduct research without requiring physical access to a laboratory.
00:00:49 Cristian: Tetsuwan raised its pre-seed round in June, 2024, led by 2048 Ventures and is deploying its prototype systems with early partners in biotech.
00:00:57 Cristian: I’m joined by Dr. Niamh O’Hara. Dr. O’Hara is the co-founder and CEO of Biotia, a healthtech company leveraging next-generation sequencing and artificial intelligence for rapid precision infectious disease discovery.
00:01:08 Cristian: A research assistant professor at SUNY Downstate Health Sciences University, Dr. O’Hara has led the groundbreaking metagenomics research, allowing her to characterize microbiomes in ambulances, hospitals, urine, and SARS-CoV-2 samples.
00:01:20 Cristian: She’s overseen the development of clinical-grade sequencing assays, such as BiotiaDx and Biotia-ID, and the GeoSeeq surveillance program, enabling rapid AI-powered pathogen detection and antimicrobial resistance tracking globally. Niamh, thanks for joining us.
00:01:33 Niamh: Thanks so much for having me. Thank you, Cristian, for your time and also really appreciate the opportunity from Everywhere. Just love being part of the Everywhere community and also being one of the portfolio companies of Everywhere.
00:01:46 Cristian: I’d love to learn more about Biotia. What are you doing and what is the impact that you hope to achieve?
00:01:52 Niamh: At Biotia, we are fighting infectious diseases powered by genomics and AI while building a leading microbial sequence database. We really see that the technology is lagging in both diagnostics and biosecurity for infectious diseases.
00:02:06 Niamh: So you can think like gold standard technology that clinicians use to identify an infection is they will use culturing. They take a sample, grow it on a petri dish, look through a microscope to identify what’s there. Fundamentally, this is technology from the 1800s. So it’s pretty wild that that’s still the gold standard in hospitals.
00:02:24 Niamh: What we’re doing is we are building more advanced diagnostics, leveraging genomics and AI so that we can more reliably identify pathogens that are causing an infection and recommend treatment for the patient. So what we’re doing is precision medicine for infectious diseases. And the outcome is quicker diagnosis, better treatment, better health outcomes for the patients, and also avoiding sepsis and death for the patients.
00:02:51 Cristian: I’m interested in where this gold standard fails. I imagine it fails in some places more than others. What does that look like? Where is there just currently not a good solution and what is Biotia doing to help out with implementing a new standard?
00:03:03 Niamh: You’re right that culturing actually does work in many cases, but we are tackling those hard to diagnose infections that culturing fails. So for example, we have a recurrent UTI product that we’ve just launched onto the market. Urine as a sample type just doesn’t do well in culture, and culturing fails about a third to half of the time for patients.
00:03:26 Niamh: And for recurrent UTI patients, which proportionately are women, they are constantly being tested, culturing fails, and they’re treated blindly. And often they’re put on these long-term courses of antibiotics, which is really bad for their system, but then also creates increased drug resistance in communities.
00:03:45 Niamh: With our solution, we are able to identify pathogens in about 70% of the samples that fail on culture. So it’s performing really well for these recurrent UTI patients. We can get them to a diagnosis and treatment which is effective.
00:04:00 Niamh: We also have announced a partnership with Hospital for Special Surgery that we are launching a prosthetic joint infection assay with them. This is for patients who just had a replacement surgery, like a hip replaced, or a shoulder, that get a subsequent infection, which is really a disaster for the patient. And treatment is very difficult, sometimes requiring a revision surgery, actually.
00:04:22 Niamh: So the diagnostic is really important. That sterile site diagnostic is challenging for culture. The perfect solution is clinical metagenomics, which is what we’re doing here.
00:04:33 Cristian: You mentioned that your platform utilizes metagenomics to provide this new standard. What is metagenomics and how does Biotia make use of it?
00:04:41 Niamh: I can briefly talk about the technology because I know I’m throwing around some jargon like genomics, metagenomics, clinical metagenomics. So what we do with the sample is we will take a sample like a urine sample or synovial fluid or wastewater. We extract DNA, RNA from that sample.
00:04:58 Niamh: We’re not interested in the human DNA in the sample. We’re really focused on the microbial DNA and RNA in the sample. We take that DNA, RNA, we break it up into tiny pieces and massively parallel sequence it on a next-gen sequencer like Illumina or Oxford Nanopore platform.
00:05:17 Niamh: We generate a lot of data from each sample, and then we have our AI software and our proprietary databases that we’ve been building with hospitals. We are able to look at the sequence data, match it up with our databases, do a bunch of machine learning on these samples as well.
00:05:33 Niamh: We’re able to identify the microbial species based on this, because we can look at that DNA sequence and see, oh, in our database this looks like E. coli. Also, we have this drug resistance gene here that’s matching up with our databases and what we’ve seen in the lab.
00:05:47 Niamh: So we can use that to better characterize what’s there. The reason why this can be really powerful is that all of these pathogens have DNA, RNA that we can look at, but not all of these pathogens can actually be cultured. So it means that we can identify those pathogens missed by culture.
00:06:02 Niamh: And it also means that it’s independent of needing to grow the pathogen and wait for the growth in which some pathogens are very slow growing or can’t be grown in culture.
00:06:13 Niamh: Different fungal species, for example, are really slow to grow. For us, turnaround time is always a day or two. Sequence everything that’s there and it can identify everything that’s there that’s in our database.
00:06:24 Cristian: Out of curiosity, when you retrieve a sample, how much of this DNA comes from human, the host, versus all the microbes and how do you split these two things apart?
00:06:33 Niamh: This is constantly a ongoing struggle in the field of clinical metagenomics. It depends on the sample type, but it’s usually very high, like 90% human and 10% microbial. It could even be higher on the human side. And for us, we consider the human a contaminant.
00:06:50 Niamh: We don’t want that data in, but you’re spending a lot of money sequencing human DNA. Then you’re masking out and focusing on the microbial. So we do a bunch of different things depending on sample type. We can amplify the microbial DNA before sequencing. We can do a human depletion step where we actually try to remove human DNA before sequencing. But sometimes a lot of these approaches often introduce some bias.
00:07:14 Niamh: You will end up depleting some of the fungi, for example, which you don’t want to do because we really are interested in fungal infections. They’re often overlooked and it’s a growing problem. Sometimes depending on the sample type, we’ll sequence more deeply. So we just have enough microbial reads and then mask the human.
00:07:31 Cristian: In Biotia’s search for pathogens, have you all discovered anything novel, novel pathogens, novel features of pathogens?
00:07:38 Niamh: Yes, which is amazing because we’re building products at Biotia, but we do a lot of R&D as well. We all have one foot in academia and one foot in industry. We had a partnership with JPL at NASA. We did a lot of work with them where we got samples from the International Space Station and characterized novel bacterial and fungal strains.
00:08:00 Niamh: We have about 10 papers with them. And we found a lot of novel strains and even species level that we identified on the ISS that had never been characterized or in databases on earth. That is interesting alien DNA, which is exciting.
00:08:15 Niamh: We also did a lot of work during COVID that we characterized some of the breakthrough variants after vaccination and then we’re tracking them in New York. We have a paper that we published on that. So a lot of work there in COVID.
00:08:28 Niamh: And then in the recurrent UTI space, we are just seeing such interesting results now because we have that product now in market and we are selling to hospitals and clinics. And we have a consumer initiated testing route that we just launched, which is clinician-mediated, clinician-led, but the patients can purchase the assay and have more access.
00:08:52 Niamh: We get a lot of patients who are coming to us with UTI symptoms. We’re finding, and they’re being treated with antibiotics. But we’re finding fungal infections and bacterial vaginosis and other pathogens that are often overlooked and mistaken to be UTIs. A lot of exciting area in women’s health and also these intractable ongoing chronic infections.
00:09:14 Cristian: That’s really cool. You mentioned that Biotia has one foot in academia and one foot in industry. Has this always been the case? What is the origin story of Biotia?
00:09:22 Niamh: It’s our origin story. We were spun out of Cornell Tech. I was doing a postdoc at Cornell Tech. They invested in us to launch Biotia. So we’re a Cornell spin-out company. My co-founder, Dr. Chris Mason, is at Weill Cornell. He’s fully an academic who has one foot in industry with us.
00:09:40 Niamh: I have an appointment at SUNY Downstate. We constantly have to rein in our tendency to do R&D and publish and redirect and focus on building the products and the revenue. But a lot of our team came out of Columbia and MIT, Weill Cornell. We’re very much in that world as well.
00:09:58 Cristian: How did you make that transition from being a researcher to being somebody who is commercializing her technology?
00:10:04 Niamh: It was a very sudden transition because I had gotten a PhD and I was doing research and applying for grant funding and publishing papers and found out about the runway program at Cornell Tech. And thought that was a really interesting alternate pathway instead of going down the full academic route.
00:10:24 Niamh: I actually had an opportunity to do a traditional academic postdoc at NYU at the same time as I got this opportunity at Cornell Tech. Chose the Cornell Tech, door number two, which was a lot scarier and weirder and turned out to be a very exciting path.
00:10:39 Niamh: Although I do still wonder, should I have done the other ones. You still reflect, but it’s turned out to open so many doors and I’ve had so much applied experience and feel like we’re really building products now that have impacts in patients’ lives, which is very exciting.
00:10:54 Niamh: But I could point that back at you. I feel like we haven’t heard much about your background and your transition. I know we talked a couple days ago and it sounded like a really exciting transition.
00:11:04 Cristian: Our current work at Tetsuwan is just a means to the end of solving a problem that I was really frustrated with in my experience with research. I started school back in North Carolina and I got involved with a bioinformatics lab on campus.
00:11:15 Cristian: There was a professor, Dr. Elizabeth Cooper, who I was just harassing with a bunch of questions about antimicrobial resistance in livestock populations. And eventually, I don’t know if she got tired of my questions. She was very patient and incredible. She offered me an internship in the lab and I immediately fell in love.
00:11:31 Cristian: At the time when we were running a genome-wide association study with Cold Spring Harbor. And for listeners who are not privy to bioinformatics, all that means is that we go and assemble a whole bunch of different genomes and we look at this thing called single nucleotide polymorphism, which is a single change, one change, one letter change in the genome.
00:11:51 Cristian: And if we try to associate these changes, these SNPs with actual visible changes, or phenotypes, in the genome that we are studying. The goal in this work was trying to understand how SNPs associate with changes that would be conducive to climate change resistance.
00:12:07 Cristian: I loved the work. I thought it was pretty magical seeing sequences fly across my laptop screen. So I transferred to Caltech, where I wanted to get away from the dry lab and into the wet lab. I worked in the lab of Dr. Kaihang Wang with a tool called Rexer & Genesis, a full genome engineering tool on a cell minimization project.
00:12:26 Cristian: Which means that we take a cell and we strip it of everything that it doesn’t need to survive so that it would be easier to re-engineer it to do a specific task. The work was unbelievably cool. Dr. Wang and the rest of the lab was an incredible group of people and I couldn’t be more grateful for Dr. Cooper and Dr. Wang.
00:12:42 Cristian: But what bench science was in my head looked a lot more like Jurassic Park and a lot less like infinite cloning. I became pretty disillusioned with a lot of the physical labor that was involved in discovery for the life sciences. So now I help build robots to do that work for us so that we could focus on the knowledge work, the ideation, the talking with our colleagues instead of being at the bench and getting Carpal Tunnel.
00:13:04 Niamh: I can really relate. Many late nights in grad school pipetting, definitely messing up my wrist and stuff. It’s really great work that you’re doing.
00:13:13 Cristian: I appreciate it. Out of curiosity, what advice would you have for those students that are there in the wet lab right now? They’re graduate students. Maybe they’re a G3 staring down the barrel of their next QPCR plate prep. What would you say to them?
00:13:27 Niamh: Depends on what lab you’re in, because you do see groups leveraging robots more, but mostly it’s undergrads, grad students. I definitely was in grad school with a number of folks that were very good at bringing on undergrad so they could hand off that work to them.
00:13:45 Niamh: And I saw people that were actually really masterful at that. Then you end up managing a bunch of undergrads and it’s actually good for the undergrads too. Maybe that’s an option. But then also I think diversifying what you’re doing.
00:13:57 Niamh: For my dissertation, I actually studied genetic responses to climate change as well in a plant population. So we have some overlap there. But I did field work, which had its own set of crazy challenges because weather and everything impacts your ability to collect data and could extend how long you’re in grad school.
00:14:15 Niamh: And then I had a big greenhouse experiment and then I had lab work. So I did like having that variation and I think it also helps connect the dots on what you’re seeing in the lab and impacts in the real world.
00:14:26 Cristian: That makes a lot of sense. Get out of the tunnel vision a little bit. Out of curiosity, who were the people who gave you advice? Who were the people who were really formative to your career?
00:14:35 Niamh: There’s just so many. My dad is a scientist. He’s a virologist. When I was eight years old, he would sit there and talk to me about HIV and how it got into the cell and those sorts of discussions. So I think that was early formative stuff.
00:14:48 Niamh: And then I have a PhD in ecology and evolution. So definitely a lot of experiences in nature, camping in nature, exposure to the natural world and just observation around that. And I had some great teachers on that front.
00:15:02 Niamh: There’s just so much schooling that I could go through all of it. But I think maybe if I just bring it back to Biotia and what’s more relevant here, the runway program at Cornell Tech and Uzi de Haan, who started that program, was really instrumental in that transition for me from thinking like a scientist, researcher, academic, into being a CEO, co-founder of a startup.
00:15:25 Niamh: We did a boot camp for the first three-year program, but the first year we sat in with the master students in business classes and then had a lot of one-on-one coaching from the folks at the runway program. Then a lot of peer support because there are a bunch of other CEOs that were starting their companies there. So we have an emotional support group going on.
00:15:45 Niamh: All of those folks have really been instrumental and then have some really great investors now who are supporting our growth and helping. Like Everywhere has been such a great support for us and other portfolio companies. Also, Michele Colucci at Digital DX and CJ at Convergent and our lead investor, Bob at OCA Ventures. Really across the board. Really wouldn’t be here without all those folks.
00:16:13 Cristian: In this path that you’ve taken alongside your mentors, the growth that you’ve had to go through to lead Biotia, what have been the most challenging obstacles?
00:16:22 Niamh: Startups inherently are challenging. You’re trying to do something that hasn’t been done before, and you’re trying to do it in a way that’s crazy with limited resources often and trying to scale rapidly. There’s been so many different challenges.
00:16:39 Niamh: We’re in a regulated space because we build diagnostic products. There’s definitely a lot of regulatory and reimbursement hurdles. The most challenging thing there is that we move really quickly with innovating and building products, but the regulatory and reimbursement moves very, very slowly, much slower than the life cycle of a lot of startups.
00:17:03 Niamh: So keeping alive to reach different milestones where you get regulatory approval and you can get your product into market, for example, is definitely a big challenge. And this is with other diagnostics companies that we talk to across the board.
00:17:16 Niamh: We built this recurrent UTI product, which is now in market, but it took years and years of development, and then it was under regulatory review for 18 months. And then we’re working on the reimbursement piece as we’re selling this like Cash Pay.
00:17:30 Niamh: Reimbursement is a unique beast in itself. Just to give you an example of this, we got a PLA code, which is like a proprietary CPT code. Then it’s going to take us another year or so to get a fee determination and coverage. While you’re working on that, you’re also improving your product but you can’t roll out the diagnostic improvements under that CPT code, under that PLA code, because that’s frozen.
00:17:57 Niamh: So you have the product that’s constantly improving, but then when you actually run the diagnostic, you have to use your old outdated tests that’s more limited because that’s the one that’s reimbursed for. So it’s really setting everyone up for this cycle that is difficult to innovate for the patients and get reimbursed for.
00:18:15 Cristian: Speaking of the patients in Biotia’s recurrent UTI product, are there certain patient stories that keep you going to overcome these obstacles and taking a product like this to market?
00:18:24 Niamh: Yeah. I myself got a hospital-acquired UTI while I was pregnant. That personal experience helped push things along for me. We just had a patient the other day who has been trying to figure out what’s going on with her for 12 months. She thought that she had E. coli. She was being treated for a standard UTI. We found urea plasma and a totally different cause and then she was able to get on the right treatment and it resolved right away.
00:18:52 Niamh: And so this is like 12 months of this struggle that we could just resolve. And we’re seeing that over and over again. It’s really heartening to see that and see the impact and feedback that we’re getting from patients.
00:19:03 Cristian: That’s amazing. What other diseases does Biotia have in its sights? What are you most excited about in Biotia’s future?
00:19:11 Niamh: We are expanding the urine testing and expanding our portfolio of diagnostics for women’s health. We’ve partnered with Mayo Clinic and we are developing an isolate assay for patients who have really weird infections that are really hard to diagnose. And that will be rolled out at Mayo. We’re licensing our software on that.
00:19:30 Niamh: And then this partnership with the Hospital for Special Surgery. It seems very clear to me that clinical metagenomics is the right solution for infections post surgery, those joint replacement surgeries. HSS is the leading orthopedics hospital. So we’re really excited to go to market with them as well and have an impact on that side.
00:19:50 Cristian: Niamh, I was super excited to get the opportunity to interview you because my interest in the life sciences originated in antimicrobial resistance. And with your incredible work in antimicrobial resistance, it’s a treat to hear more about your work. For our viewers, what is antimicrobial resistance? Why is it a problem and how is Biotia helping?
00:20:09 Niamh: Antimicrobial resistance is a trait that the pathogen acquires or evolves where they are not impacted by an antimicrobial, like an antibiotic. So we basically think that you have an infection. If the pathogen causing your infection is drug resistant, you take the drug and the pathogen doesn’t care. It is not impacted by the drug.
00:20:32 Niamh: People often misunderstand and think that antimicrobial resistance is a trait of the human, like yourself, but it’s actually the pathogens. This is a growing problem globally. It’s projected to be one of the leading causes of death by 2050. And it’s because we overuse and misuse antimicrobials, antibiotics.
00:20:53 Niamh: Antibiotics have been one of the greatest discoveries in scientific history and been the savior and cause of a big decrease in deaths. And so losing them is very scary. There aren’t many antimicrobials that are going to market because of financial incentives and IP regulation. So pharma really aren’t creating many new antimicrobials.
00:21:19 Niamh: There is hope with different emerging therapies like phage. So really excited about those discoveries and advancements. But something that we’re doing to address this problem is more judicious use and appropriate use of antimicrobials.
00:21:34 Niamh: If we can diagnose the patient and show what drug resistance they have, then the patient can be treated in a precision manner tailored to their infection and resolve their infection faster. So it means that you see a slowing of increase in drug resistance.
00:21;51 Niamh: I know that you guys are enabling a lot of work for researchers and you have an interest in AMR. Just interested to hear you talk about the problem from your perspective and how you guys might be able to impact that.
00:22:03 Cristian: I couldn’t have said it better when you say that judicious use is one of the best things that we can do to slow AMR. There are some early lab automation systems that leverage metagenomics to enable the rapid and more precise determination of effective microbial regimens. And this is pretty incredible.
00:22:19 Cristian: For viewers who are unfamiliar with a lot of the nuances of antimicrobial resistance, it is, unfortunately, common for patients to receive incorrect regimens or to receive antimicrobials that would not be effective in targeting their infection and this only further builds resistance in the population and worsens the problem of antimicrobial resistance.
00:22:39 Cristian: Not only that, but patients who suffer from severe infections may suffer from sepsis if they are not given the correct regimen of antimicrobials before the infection really takes off. But fortunately, we have a set of drugs called drugs of last resort. These drugs are often older antimicrobials. They’re not really used a lot. A lot of them cause things like liver damage. They’re not super safe.
00:23:03 Cristian: When somebody gets really sick and they just have a whole bunch of resistance to all of these common antimicrobials, we have these drugs of last resort to save them. The really scary thing and what got me into this a few years ago was that one of these drugs of last resort, colistin, I believe an antimicrobial from a long time ago that caused liver damage in patients and is pretty highly regulated, had been used in swine farms in China.
00:23:27 Cristian: These pigs had developed a resistance to colistin and the gene had transferred over to microbes that infect humans. This is really bad. Hopefully, fingers crossed, the combination of metagenomics and lab automation can ensure that we have a more rapid answer to this problem. How has commercialization been going so far with Biotia-ID?
00:23:49 Niamh: It’s been really exciting because I mentioned it’s this long pathway of development, regulatory review, and we now have the product in market for the Biotia-ID urine assay. We have just received regulatory approval in all 50 states. So it’s the only clinical metagenomics assay, which is sold in all 50 states.
00:24:07 Niamh: We have been selling to clinics and hospitals and just recently launched the consumer initiated testing route so that patients can receive a complete care pathway with our telehealth partner who can requisition the test for them. They can collect a sample at home, send it in to us and get treatment with the telehealth partner. So that’s been really exciting.
00:24:27 Niamh: We also have some great partnership opportunities that are coming in. So we’re at the stage that we are really scaling and seeing this great traction in the market. So that also has kicked off a fundraise. So we’re fundraising now in order to be able to scale and plant the product more firmly in the market.
00:24:47 Cristian: Niamh, I’d love to get into the speed round questions. First one being, what’s a book, newsletter or podcast that you’ve been enjoying recently?
00:24:55 Niamh: This is maybe a little bit off topic, but I think that with everything going on with shifting landscape in our country and funding into science, for me, something that’s been really helpful is I’ve been listening to this podcast called All the Presidents, Man, which is basically this middle school and high school history teacher who’s just talking to his friend who makes podcasts and stuff.
00:25:18 Niamh: He’s just going off the cuff and just talking about each president and gives this incredible context, which I’m just finding to be comforting and also really just interesting to understand a little bit more about dynamics in the country and what’s happening now and what we’ve seen before.
00:25:35 Cristian: If you could live anywhere in the world for one year, where would it be?
00:25:38 Niamh: Recently, my husband and I have been talking about doing a sabbatical at some point in Barcelona. We went and visited there. It was such an exciting city. Really loved it.
00:25:48 Cristian: What’s your favorite productivity hack?
00:25:50 Niamh: There’s a million great AI tools, but mentally my productivity hack, that is something I’ve developed over time, is just starting at the end. So when I am thinking about a project or something I’m working on that has many stages, I will work from the end back. So end step is sending out an email that’s giving an update on all of these things that I did. I will start drafting the email and then work backwards. And that just seems to work for my brain.
00:26:14 Cristian: Finally, where can listers find you?
00:26:17 Niamh: I am not super active on social media. Luckily we brought on other folks on the team that are better at that. But you can find me on LinkedIn or you can email me at ohara@biotia.io. And LinkedIn, I’m under Niamh B. O’Hara. Happy to chat with people.
00:26:35 Cristian: Well, Niamh, thank you for joining.
00:26:37 Niamh: Thank you. Thanks so much for your time and thanks to Everywhere as well. Great to be here.
00:26:42 Scott Hartley: Thanks for joining us and hope you enjoyed today’s episode. For those of you listening, you might also be interested to learn more about Everywhere. We’re a first-check pre-seed fund that does exactly that, invests everywhere. We’re a community of 500 founders and operators, and we’ve invested in over 250 companies around the globe. Find us at our website, Everywhere.vc, on LinkedIn, and through our regular founder spotlights on Substack. Be sure to subscribe and we’ll catch you on the next episode.
Read more from Niamh O’Hara in Founders Everywhere.
Read more from Cristian Ponce in Founders Everywhere.